Document:

Letter Agreement

 Exhibit 10.26 
 Hand-Delivered 
 November 5, 2009 
 Eric Rodli 
 4834 Oakwood Avenue 
 La Canada, CA 91011 
 Re:
Separation and Release 
 Dear Mr. Rodli: 
 This letter agreement (the “Agreement”) will confirm our termination of your employment with DivX, Inc. (“DXN”) effective November 5, 2009 (where each of “you”
and “DXN” shall be a “Party” or “Parties” under this Agreement as applicable). 
 Concurrent with this
letter, I am delivering to you 3 checks totaling $10,579.94, reflecting payment to you of $5,384.41 for salary through November 5, 2009 less applicable withholdings, for PTO equal to 38.65 hours, and for housing stipend for
the month of November equal to $4,000.00, less applicable withholdings (“Salary/PTO Payment/Housing Stipend”). Within thirty (30) days of the date of this Agreement, you will receive notification from Benefits
Coordinators Corp. (BCC) regarding your COBRA benefits.  
 Please refer to the attached Closing Statement regarding the current status
of your options and the time for exercising such options. Should you have any questions, please contact the stock administrator, Victoria Feroni (vferoni@divxcorp.com or 1-858-882-0633). 
 In exchange for your agreement to the terms contained in this Agreement, and subject to your continued adherence to the terms and conditions of the
confidentiality agreement entered into by and between you and DXN, DXN will: (a) pay you severance equal to three (3) months of salary (gross payment of $87,500.04) less applicable withholdings (“Severance
Payment”); (b) pay you a Q3 2009 bonus of $87,500.04, less applicable withholdings, which bonus will be paid at such time as Q3, 2009 bonuses are paid to eligible employees (“Bonus Payment”); and
(c) assume, and hold you harmless from, any lease payments or other obligations under the remainder of the lease (starting December 1, 2009) for the apartment (“Apartment”) at 777 Solana Circle East, Solana Beach, CA 92075
(“Lease Assumption”) and refund the $5,500 security and pet deposit you previously paid out of pocket with respect to the Apartment (“Deposit Refund”). 
 You acknowledge and agree that you shall receive no other salary, bonus or other payment from DXN other than the Salary/PTO/Housing Stipend Payment, Severance Payment, Bonus Payment,
Deposit Refund and Lease Assumption. 
 Each Party agrees to release the other Party, as well as its past and present officers,
directors, employees, agents, and any affiliated entities, (“Released Parties”) from any and all liability related to or arising out of your employment with or separation from DXN or from any events, transactions or occurrences between you
and DXN to date. This release specifically includes, but is not limited to, any claims for wages, benefits, or premium pay, wrongful discharge, retaliation, breach of implied contract, breach of implied covenant of good faith and fair
dealing, harassment or discrimination and/or violation of any statutes, rules, regulations or ordinances, whether federal, state or local, including, but not limited to, Title VII of the Civil Rights Act of 1964, as amended, age claims under the Age
Discrimination in Employment Act of 1967, as amended by the Older Workers Benefits Protection Act of 1990, Section 1981 of Title 42 of the United States Code, and the California Fair Employment and Housing Act, provided, however, that with
respect to DXN’s release of you and your Released Parties as set forth in this paragraph, such release shall exclude acts of moral turpitude, gross negligence or willful misconduct by you. 

 Further, you agree that this release is to be interpreted broadly and includes the waiver of all rights
under California Civil Code section 1542, which provides that: 
 A general release does not extend to claims which the
creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor. 
 You represent and agree that, prior to the execution of this Agreement, you have had the opportunity to discuss the terms of this Agreement with legal counsel of your choosing. 
 Notwithstanding anything to the contrary in this Agreement, with respect to your period of employment at DXN nothing in this Agreement shall affect any
prior or existing rights or obligations you may have under that certain Indemnity Agreement dated March 13, 2009 between you and DXN (“Indemnity Agreement”), under DXN’s D&O, E&O or CGL insurance policies, or under
the indemnification provisions of DXN’s Amended and Restated Bylaws. For the sake of clarity, DXN acknowledges and agrees that the termination as set forth in this Agreement shall be considered a “Covered Termination” for the purposes
of that certain Change in Control Severance Benefit Plan as entered into between you and DXN pursuant to the March 13, 2009 Participation Notice. 
 By signing this Agreement, you are agreeing that you have not filed any claims against DXN or any of the other Released Parties in any court or with any governmental agency and, except as otherwise required or permitted by law, you will not
prosecute, nor allow to be prosecuted on your behalf, in any state or federal court or administrative agency, any claim related to the matters released in this Agreement. Notwithstanding the foregoing, you acknowledge that you are not giving up any
rights or claims under the federal Age Discrimination in Employment Act that may arise after the date this Agreement is executed. 
 In
addition, you agree that you will return by November 12, 2009 all DXN property, data, and information belonging to DXN and agree that you will not use or disclose to others any confidential or proprietary information of DXN or the other
Released Parties. You further agree to comply with the continuing obligations set forth in the agreement you signed at the time you were hired regarding confidentiality. In addition, both Parties agree to keep the terms of this Agreement
confidential between you and DXN, except that you may tell your immediate family, and either Party may discuss the terms of this Agreement with each Parties’ respective attorneys, consultants, bankers, advisors or accountants, if any and as
needed, or other third parties if required by law; but in no event should you discuss this Agreement or its terms with any current or prospective employee of DXN. 
 Each Party also agrees that it will not act in any manner that might damage the other Party’s business or reputation, or the business or reputation of any of the other Released
Parties. You further agree that you will not counsel or assist any third parties, or their attorneys, in the preparation, presentation, or prosecution of any disputes, differences, grievances, claims, charges, or complaints
by any third party against DXN and/or against any of the other Released Parties, unless under a subpoena or other court order to do so. You further agree that you will reasonably assist DXN, and its attorneys, at DXN’s cost, in the preparation,
presentation, or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against DXN and/or against any of the other Released Parties. 
 This Agreement is not an admission by DXN or the other Released Parties that they have engaged, or are now engaging, in any unlawful conduct. DXN and the other Released Parties specifically deny any
liability and intend merely to achieve an amicable separation by securing this release of all claims. 

 This Agreement shall be construed under the laws of the State of California, both procedural and
substantive. The Parties consent to the exclusive jurisdiction of the Superior Court of the County of San Diego (Central District) to resolve any dispute regarding this Agreement. 
 You acknowledge that you have been advised that you have forty-five (45) days to consider this Agreement and that you were informed that you have the right to consult with counsel regarding this
Agreement. To the extent you have taken less than forty-five (45) days to consider this Agreement, you acknowledge that you have had sufficient time to consider the Agreement and to consult with counsel and that you do not desire additional
time. 
 This Agreement is revocable by you for a period of seven (7) days following your execution of this Agreement. The revocation by
you of this Agreement must be in writing, must specifically revoke this Agreement, and must be received by DXN prior to the eighth (8th) day following the execution of this Agreement by you. This Agreement becomes effective, enforceable and
irrevocable on the eighth (8th) day following your execution of the Agreement and will not become effective or enforceable in the event that you revoke it. 
 This Agreement is intended to be a binding legal document. This Agreement, together with the confidentiality agreement signed by you, sets forth the entire agreement between you and DXN and shall be
binding upon each party’s heirs, representatives and successors and supersedes any prior agreement on this subject. No amendments to this Agreement will be valid unless written and signed by you and an officer of DXN. 
 If the foregoing terms and conditions are entirely satisfactory to you, please date and sign the Agreement below and return the original to me. 

Sincerely, 
  

							
	DivX, Inc.
				
	By:	  	 /s/ Johnny Y. Chen
	  		  	 Nov. 5, 2009

		  	Johnny Y. Chen	  		  	Date
		  	General Counsel	  		  	
	
	ACKNOWLEDGED AND AGREED:
				
		  	 /s/ Eric Rodli
	  		  	 Nov 16, 2009 

		  	Eric Rodli	  		  	DateSecond Amendment to the Exclusive License and Collaboration Agreement

 [ * ] = Certain information on this document has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  
 Exhibit 10.74 
 SECOND AMENDMENT 
 TO 
 EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT 
 This Second Amendment (“Second
Amendment”) to the Exclusive License and Collaboration Agreement effective as of October 16, 2006 (as amended by that certain First Amendment effective as of October 16, 2008 (“First Amendment”)) (collectively,
the “Agreement”) is made effective as of October 16, 2009 (the “Second Amendment Effective Date”) and entered into by and between Hoffmann-La Roche Inc., a New Jersey corporation located at 340 Kingsland
Street, Nutley, New Jersey 07110 (“Roche Nutley”), and F.Hoffmann-La Roche Ltd, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (“Roche Basel”; Roche Nutley
and Roche Basel are collectively referred to as “Roche”), on the one hand, and InterMune, Inc., a Delaware corporation with its principal place of business at 3280 Bayshore Boulevard, Brisbane, California 94005
(“InterMune”), on the other hand. 
 WHEREAS, InterMune and Roche wish to enter into
this Amendment to the Agreement to (i) further extend the Research Program Term (and consequently the [ * ]) for an additional amount of time set forth herein; (ii) provide for Roche’s ongoing funding of a certain
number of InterMune FTEs assigned to the Research Program as well as certain Third Party vendor costs incurred in connection with the Research Program during the extended Research Program Term; (iii) provide Roche a credit for such funding
amounts against certain future Licensed Compound Payment(s); and (iv) to extend the period during which Roche may add or substitute Licensed Compounds following the expiration of the Research Program Extension Term. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for good
and valuable consideration, the receipt and sufficiency which are hereby acknowledged, Roche and InterMune hereby agree as follows: 
  

	1.	 Any capitalized term not otherwise defined herein shall have the meaning ascribed to it in the Agreement. 

  

	2.	 The Parties acknowledge and agree that the Research Program Term (as previously extended by the First Amendment) expired on [ * ]
under the existing terms and conditions of the Agreement. The Parties hereby agree to extend further the Research Program Term from [ * ] until [ * ] (the “Further Extended Research Program Term”).
As a result of this Second Amendment, the definition of “Research Program Term” for purposes of the Agreement shall include the Further Extended Research Program Term, with the express exception of Section 12.2 of the Agreement. The
Parties agree that the [ * ] provided for in the Agreement (as previously extended by the First Amendment) shall [ * ]. 

  

	3.	 The Parties shall work together to modify the Research Plan, as appropriate, to specify the ongoing activities of the Research Program during the
Further Extended Research Program Term consistent with the guidelines set forth in Schedule 1.1 attached to this Second

  

 1 

 [ * ] = Certain information on this document has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	 	 
Amendment (“Schedule 1.1”). For purposes of the Further Extended Research Program Term, the definition of “Research Program” under the Agreement, as amended by the
First Amendment and this Second Amendment, shall include those activities contemplated in the revised Research Plan. 

  

	4.	 The Parties acknowledge and agree that as of the Second Amendment Effective Date, pursuant to the First Amendment, Roche is currently funding
[ * ] ([ * ]) InterMune FTEs assigned to the Research Program. The Parties hereby agree that Roche shall continue to fund [ * ] percent ([ * ]%) of the Research Program activities
as follows: 

  

	 	A.	 Until [ * ], Roche shall continue to fund [ * ] ([ * ]) InterMune FTEs assigned to the Research
Program at an FTE rate equal to CHF [ * ] ([ * ]). As also provided in the First Amendment, on a Calendar Quarter basis, InterMune shall invoice Roche for the actual FTEs used at the FTE rate set forth herein that
were incurred during the relevant Calendar Quarter and payment for each invoice shall be made by Roche to InterMune at the same time cash settlement is made between the Parties based on the Reconciliation Statement process described in
Section 1.6 of Exhibit A attached to the Agreement. 

  

	 	B.	 Until [ * ], Roche shall [ * ], which use shall be consistent with the Research Plan and the guidelines set forth
in Schedule 1.1. Furthermore, as also provided in the First Amendment, the Parties agree that the JRC shall continually review, discuss and monitor the use of various Third Party vendors and the incurrence of costs from such use. On a
Calendar Quarter basis, InterMune shall provide to Roche copies of all invoices received by such Third Party vendors to evidence such actual costs incurred during the relevant Calendar Quarter and [ * ].

  

	5.	 In the event InterMune undergoes and closes a Change of Control transaction at any time during the Further Extended Research Program Term, the
Further Extended Research Program Term and the [ * ] shall automatically terminate upon the closing of such Change of Control transaction. However, Roche’s obligation to [ * ] of termination of the Further
Extended Research Program Term shall survive such early termination and Roche will also [ * ] as a result of the Research Program. 

  

	6.	 Roche shall have the right to credit [ * ] percent ([ * ]%) of all amounts paid by Roche to InterMune to fund the
Research Program during the Further Extended Research Program Term against any Licensed Compound Payment(s) otherwise due and payable to InterMune pursuant to Section 5.3.3 of the Agreement in connection with the designation by Roche of
additional Licensed Compounds. 

  

	7.	 The period of time during which Roche has the right to add or substitute Licensed Compounds pursuant to Sections 5.3.3 and 5.3.2 of the Agreement
shall be extended for a period of [ * ] ([ * ]) months following the expiration of the Further Extended Research Program Term. 

  

	8.	 Notwithstanding anything to the contrary contained in Article 7, Roche may disclose InterMune Confidential Information to Genentech or Chugai solely
for the purposes of allowing Genentech or Chugai to decide whether to be included as an Affiliate and provided

  

 2 

 [ * ] = Certain information on this document has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

	 	 
that Roche first informs Genentech and/or Chugai, as appropriate, of the confidential nature of the InterMune Confidential Information and ensures that Genentech and/or Chugai, as appropriate,
are bound by terms and conditions substantially equivalent to those in Article 7 as they apply to Roche. 

  

	9.	 Except as specifically modified and amended by this Second Amendment, the Agreement (including the First Amendment) remains unchanged and in full
effect between the Parties. 

  

	10.	 This Second Amendment may be signed by the parties in counterparts, which signatures, taken as a whole, shall constitute a single effective
agreement. 

 [Signature Page Follows] 
  

 3 

 [ * ] = Certain information on this document has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 IN WITNESS WHEREOF, the Parties have executed this Second Amendment as of the
Second Amendment Effective Date. 
  

					
	HOFFMANN-LA ROCHE INC.	  	INTERMUNE, INC.	  	
			
	BY: /s/ Nader Fotouhi	  	BY: /s/ John Hodgman	  	
			
	NAME: Nader Fotouhi	  	NAME: John Hodgman	  	
			
	TITLE: VP, Discovery Chemistry	  	TITLE: Senior Vice President and CFO	  	
			
	DATE: November 4, 2009	  	DATE: November 4, 2009	  	
			
	F.HOFFMANN-LA ROCHE LTD	  		  	
			
	BY: /s/ Stefan Arnold	  		  	
			
	NAME: Stefan Arnold	  		  	
			
	TITLE: Head Corporate Law Pharma	  		  	
			
	DATE: November 5, 2009	  		  	
			
	BY: /s/ Christophe Carissimo	  		  	
			
	NAME: Christophe Carissimo	  		  	
			
	TITLE: Global Licensing Director	  		  	
			
	DATE: November 5, 2009	  		  	

  

 4 

 [ * ] = Certain information on this document has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 SCHEDULE 1.1 
 GUIDELINES FOR EXTENSION OF RESEARCH PROGRAM 
 InterMune and Roche will continue to collaborate on the discovery and preclinical development of [ * ]. 
 The primary purpose of the extension of the Research Program is to nominate and develop [ * ] and the potential for [ * ]. The Parties anticipate that during the extension period, InterMune will disclose in
more detail InterMune Know-How to Roche concerning [ * ], the use of which by Roche shall be expressly subject to the scope of the license grants by InterMune to Roche under the Agreement. 
  

			
	Estimated FTE	  	 
	 	  	10/09 to 12/09
	 Synthetic chemistry
	  	[ * ]
	 Computational chemistry/Roche functional area liaison
	  	[ * ]
	 CRO manager/Lead medicinal chemist/Roche functional area liaison
	  	[ * ]
	 Compound screening/Kinetic characterization/mutant enzyme activity
	  	[ * ]
	 Biochemistry management/ Roche functional area liaison
	  	[ * ]
	 Compound screening/Antiviral activity characterization (clearance,
synergy)
	  	[ * ]
	 Biology management/Roche functional area liaison
	  	[ * ]
	 Toxicology
	  	[ * ]
	 Formulation
	  	[ * ]
	 Bioanalytics
	  	[ * ]
	 ADME
	  	[ * ]
	 DMPK management/Roche functional area
liaison
	  	[ * ]
	Total  	  	[ * ]
		  	
	**Estimated pass through cost (US$ in thousands)	  	 
	 	  	10/09 to 12/09
	 Synthetic chemistry
	  	$[ * ]
	 Structural Biology
	  	$[ * ]
	 PK
	  	$[ * ]
	 Protein Production
	  	$[ * ]
	 License Fees
	  	$[ * ]
	Total  	  	$[ * ]

 ** Current good faith estimate only. Actual costs may differ. 
  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]